Online inquiry

IVTScrip™ mRNA-Anti-APP, PF-04360365(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ13126MR)

This product GTTS-WQ13126MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets APP gene. The antibody can be applied in Alzheimer's disease (AD) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_000484.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 351
UniProt ID P05067
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-APP, PF-04360365(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ13126MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ10347MR IVTScrip™ mRNA-Anti-IL17A&TNFSF13B, LY 3090106(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA LY 3090106
GTTS-WQ14436MR IVTScrip™ mRNA-Anti-IGF1R, RO4858696-000(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA RO4858696-000
GTTS-WQ9352MR IVTScrip™ mRNA-Anti-PDCD1, INCMGA-00012(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA INCMGA-00012
GTTS-WQ7137MR IVTScrip™ mRNA-Anti-LHCGR, FE 999302(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA FE 999302
GTTS-WQ6311MR IVTScrip™ mRNA-Anti-TNFRSF10B, CS-1008(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CS-1008
GTTS-WQ5930MR IVTScrip™ mRNA-Anti-CD274, CK-301(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA CK-301
GTTS-WQ11219MR IVTScrip™ mRNA-Anti-pcrV&psl, MEDI3902(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MEDI3902
GTTS-WQ11628MR IVTScrip™ mRNA-Anti-LAG3&PDCD1, MGD-013(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MGD-013
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW